Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
Innovation & Entrepreneurship
Strategy / MBA Resources
Case Study SWOT Analysis Solution
Case Study Description of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets
This case explores the difficulties involved in commercialising vaccines in low-income settings. The focus is the dengue vaccine, launched at the end of 2015, which was first commercialised in emerging markets. It considers issues of affordability and distribution, higlighting the need for business model innovation in all industries.
Swot Analysis of "Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets" written by Philip Parker, Pierfitte Marion includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Vaccine Dengue facing as an external strategic factors. Some of the topics covered in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study are - Strategic Management Strategies, Health and Innovation & Entrepreneurship.
Some of the macro environment factors that can be used to understand the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets casestudy better are - – banking and financial system is disrupted by Bitcoin and other crypto currencies, customer relationship management is fast transforming because of increasing concerns over data privacy, technology disruption, increasing government debt because of Covid-19 spendings, digital marketing is dominated by two big players Facebook and Google, geopolitical disruptions, wage bills are increasing,
increasing energy prices, cloud computing is disrupting traditional business models, etc
Introduction to SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Vaccine Dengue, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Vaccine Dengue operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets can be done for the following purposes –
1. Strategic planning using facts provided in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study
2. Improving business portfolio management of Vaccine Dengue
3. Assessing feasibility of the new initiative in Innovation & Entrepreneurship field.
4. Making a Innovation & Entrepreneurship topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Vaccine Dengue
Strengths Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Vaccine Dengue in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study are -
Successful track record of launching new products
– Vaccine Dengue has launched numerous new products in last few years, keeping in mind evolving customer preferences and competitive pressures. Vaccine Dengue has effective processes in place that helps in exploring new product needs, doing quick pilot testing, and then launching the products quickly using its extensive distribution network.
Effective Research and Development (R&D)
– Vaccine Dengue has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in, as mentioned in case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets - staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
Learning organization
- Vaccine Dengue is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Vaccine Dengue is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study emphasize – knowledge, initiative, and innovation.
Organizational Resilience of Vaccine Dengue
– The covid-19 pandemic has put organizational resilience at the centre of everthing that Vaccine Dengue does. Organizational resilience comprises - Financial Resilience, Operational Resilience, Technological Resilience, Organizational Resilience, Business Model Resilience, and Reputation Resilience.
Ability to recruit top talent
– Vaccine Dengue is one of the leading recruiters in the industry. Managers in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are in a position to attract the best talent available. The firm has a robust talent identification program that helps in identifying the brightest.
Analytics focus
– Vaccine Dengue is putting a lot of focus on utilizing the power of analytics in business decision making. This has put it among the leading players in the industry. The technology infrastructure suggested by Philip Parker, Pierfitte Marion can also help it to harness the power of analytics for – marketing optimization, demand forecasting, customer relationship management, inventory management, information sharing across the value chain etc.
Digital Transformation in Innovation & Entrepreneurship segment
- digital transformation varies from industry to industry. For Vaccine Dengue digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Vaccine Dengue has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Low bargaining power of suppliers
– Suppliers of Vaccine Dengue in the sector have low bargaining power. Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets has further diversified its suppliers portfolio by building a robust supply chain across various countries. This helps Vaccine Dengue to manage not only supply disruptions but also source products at highly competitive prices.
Operational resilience
– The operational resilience strategy in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study comprises – understanding the underlying the factors in the industry, building diversified operations across different geographies so that disruption in one part of the world doesn’t impact the overall performance of the firm, and integrating the various business operations and processes through its digital transformation drive.
Cross disciplinary teams
– Horizontal connected teams at the Vaccine Dengue are driving operational speed, building greater agility, and keeping the organization nimble to compete with new competitors. It helps are organization to ideate new ideas, and execute them swiftly in the marketplace.
Sustainable margins compare to other players in Innovation & Entrepreneurship industry
– Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets firm has clearly differentiated products in the market place. This has enabled Vaccine Dengue to fetch slight price premium compare to the competitors in the Innovation & Entrepreneurship industry. The sustainable margins have also helped Vaccine Dengue to invest into research and development (R&D) and innovation.
Superior customer experience
– The customer experience strategy of Vaccine Dengue in the segment is based on four key concepts – personalization, simplification of complex needs, prompt response, and continuous engagement.
Weaknesses Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Slow to strategic competitive environment developments
– As Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets HBR case study mentions - Vaccine Dengue takes time to assess the upcoming competitions. This has led to missing out on atleast 2-3 big opportunities in the industry in last five years.
Ability to respond to the competition
– As the decision making is very deliberative, highlighted in the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, in the dynamic environment Vaccine Dengue has struggled to respond to the nimble upstart competition. Vaccine Dengue has reasonably good record with similar level competitors but it has struggled with new entrants taking away niches of its business.
Low market penetration in new markets
– Outside its home market of Vaccine Dengue, firm in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets needs to spend more promotional, marketing, and advertising efforts to penetrate international markets.
Workers concerns about automation
– As automation is fast increasing in the segment, Vaccine Dengue needs to come up with a strategy to reduce the workers concern regarding automation. Without a clear strategy, it could lead to disruption and uncertainty within the organization.
High operating costs
– Compare to the competitors, firm in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets has high operating costs in the. This can be harder to sustain given the new emerging competition from nimble players who are using technology to attract Vaccine Dengue 's lucrative customers.
Need for greater diversity
– Vaccine Dengue has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
Capital Spending Reduction
– Even during the low interest decade, Vaccine Dengue has not been able to do capital spending to the tune of the competition. This has resulted into fewer innovations and company facing stiff competition from both existing competitors and new entrants who are disrupting the industry using digital technology.
Compensation and incentives
– The revenue per employee as mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, is just above the industry average. Vaccine Dengue needs to redesign the compensation structure and incentives to increase the revenue per employees. Some of the steps that it can take are – hiring more specialists on project basis, etc.
High bargaining power of channel partners
– Because of the regulatory requirements, Philip Parker, Pierfitte Marion suggests that, Vaccine Dengue is facing high bargaining power of the channel partners. So far it has not able to streamline the operations to reduce the bargaining power of the value chain partners in the industry.
High cash cycle compare to competitors
Vaccine Dengue has a high cash cycle compare to other players in the industry. It needs to shorten the cash cycle by 12% to be more competitive in the marketplace, reduce inventory costs, and be more profitable.
Slow decision making process
– As mentioned earlier in the report, Vaccine Dengue has a very deliberative decision making approach. This approach has resulted in prudent decisions, but it has also resulted in missing opportunities in the industry over the last five years. Vaccine Dengue even though has strong showing on digital transformation primary two stages, it has struggled to capitalize the power of digital transformation in marketing efforts and new venture efforts.
Opportunities Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Learning at scale
– Online learning technologies has now opened space for Vaccine Dengue to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Leveraging digital technologies
– Vaccine Dengue can leverage digital technologies such as artificial intelligence and machine learning to automate the production process, customer analytics to get better insights into consumer behavior, realtime digital dashboards to get better sales tracking, logistics and transportation, product tracking, etc.
Reconfiguring business model
– The expansion of digital payment system, the bringing down of international transactions costs using Bitcoin and other blockchain based currencies, etc can help Vaccine Dengue to reconfigure its entire business model. For example it can used blockchain based technologies to reduce piracy of its products in the big markets such as China. Secondly it can use the popularity of e-commerce in various developing markets to build a Direct to Customer business model rather than the current Channel Heavy distribution network.
Manufacturing automation
– Vaccine Dengue can use the latest technology developments to improve its manufacturing and designing process in Innovation & Entrepreneurship segment. It can use CAD and 3D printing to build a quick prototype and pilot testing products. It can leverage automation using machine learning and artificial intelligence to do faster production at lowers costs, and it can leverage the growth in satellite and tracking technologies to improve inventory management, transportation, and shipping.
Using analytics as competitive advantage
– Vaccine Dengue has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in the sector. This continuous investment in analytics has enabled, as illustrated in the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets - to build a competitive advantage using analytics. The analytics driven competitive advantage can help Vaccine Dengue to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Vaccine Dengue is facing challenges because of the dominance of functional experts in the organization. Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study suggests that firm can utilize new technology to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Loyalty marketing
– Vaccine Dengue has focused on building a highly responsive customer relationship management platform. This platform is built on in-house data and driven by analytics and artificial intelligence. The customer analytics can help the organization to fine tune its loyalty marketing efforts, increase the wallet share of the organization, reduce wastage on mainstream advertising spending, build better pricing strategies using personalization, etc.
Low interest rates
– Even though inflation is raising its head in most developed economies, Vaccine Dengue can still utilize the low interest rates to borrow money for capital investment. Secondly it can also use the increase of government spending in infrastructure projects to get new business.
Use of Bitcoin and other crypto currencies for transactions
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Vaccine Dengue in the consumer business. Now Vaccine Dengue can target international markets with far fewer capital restrictions requirements than the existing system.
Identify volunteer opportunities
– Covid-19 has impacted working population in two ways – it has led to people soul searching about their professional choices, resulting in mass resignation. Secondly it has encouraged people to do things that they are passionate about. This has opened opportunities for businesses to build volunteer oriented socially driven projects. Vaccine Dengue can explore opportunities that can attract volunteers and are consistent with its mission and vision.
Changes in consumer behavior post Covid-19
– Consumer behavior has changed in the Innovation & Entrepreneurship industry because of Covid-19 restrictions. Some of this behavior will stay once things get back to normal. Vaccine Dengue can take advantage of these changes in consumer behavior to build a far more efficient business model. For example consumer regular ordering of products can reduce both last mile delivery costs and market penetration costs. Vaccine Dengue can further use this consumer data to build better customer loyalty, provide better products and service collection, and improve the value proposition in inflationary times.
Building a culture of innovation
– managers at Vaccine Dengue can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the Innovation & Entrepreneurship segment.
Better consumer reach
– The expansion of the 5G network will help Vaccine Dengue to increase its market reach. Vaccine Dengue will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Threats Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Easy access to finance
– Easy access to finance in Innovation & Entrepreneurship field will also reduce the barriers to entry in the industry, thus putting downward pressure on the prices because of increasing competition. Vaccine Dengue can utilize it by borrowing at lower rates and invest it into research and development, capital expenditure to fortify its core competitive advantage.
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
Technology acceleration in Forth Industrial Revolution
– Vaccine Dengue has witnessed rapid integration of technology during Covid-19 in the Innovation & Entrepreneurship industry. As one of the leading players in the industry, Vaccine Dengue needs to keep up with the evolution of technology in the Innovation & Entrepreneurship sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
Stagnating economy with rate increase
– Vaccine Dengue can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the field.
Regulatory challenges
– Vaccine Dengue needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the Innovation & Entrepreneurship industry regulations.
Environmental challenges
– Vaccine Dengue needs to have a robust strategy against the disruptions arising from climate change and energy requirements. EU has identified it as key priority area and spending 30% of its 880 billion Euros European post Covid-19 recovery funds on green technology. Vaccine Dengue can take advantage of this fund but it will also bring new competitors in the Innovation & Entrepreneurship industry.
Shortening product life cycle
– it is one of the major threat that Vaccine Dengue is facing in Innovation & Entrepreneurship sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Instability in the European markets
– European Union markets are facing three big challenges post Covid – expanded balance sheets, Brexit related business disruption, and aggressive Russia looking to distract the existing security mechanism. Vaccine Dengue will face different problems in different parts of Europe. For example it will face inflationary pressures in UK, France, and Germany, balance sheet expansion and demand challenges in Southern European countries, and geopolitical instability in the Eastern Europe.
Increasing wage structure of Vaccine Dengue
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Vaccine Dengue.
Backlash against dominant players
– US Congress and other legislative arms of the government are getting tough on big business especially technology companies. The digital arm of Vaccine Dengue business can come under increasing regulations regarding data privacy, data security, etc.
High dependence on third party suppliers
– Vaccine Dengue high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Vaccine Dengue in the Innovation & Entrepreneurship sector and impact the bottomline of the organization.
Weighted SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Vaccine Dengue needs to make to build a sustainable competitive advantage.
Feel free to connect with us if you need business research.
You can download Excel Template of Case Study Solution & Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets